皇冠体育app

BEIJING - Tasly Pharmaceutical Group Co Ltd, a leading pharmaceutical company in 皇冠体育app, said Saturday that its net profit in the first half of the year rose 24.04 percent year on year to 744.5 million yuan ($120.9 million).

Business revenues rose 13.07 percent from a year earlier to 6.1 billion yuan, according to the company's interim report.

Earning per share for the period stood at 0.72 yuan.

Tasly is one of 皇冠体育app's largest producers of traditional Chinese medicines. Its business scope also includes chemical and biological drugs, healthcare products, and functional foods.

Pharmaceutical sector ripe for innovation	Cloud initiative helps promote health service

• 皇冠体育app expert puts US relations on the couch
• 皇冠体育app's new companies surge after registration reform
• Cellular medicine has new desktop solution
• Lock-up shares worth 42.6b yuan eligible for trade
• Chinese light industry profits rise, margin squeezed
• 皇冠体育app's July trade figures are encouraging and worrying
• 皇冠体育app under little inflationary pressure in H2: analyst
• 皇冠体育app advances property tax reforms amid slowdown